Avoro Capital Advisors LLC 13F holdings, Q4 2024
Holdings as of December 31, 2024 · filings on SEC EDGAR · latest filing →
Avoro Capital Advisors LLC disclosed 39 US equity positions worth $7.1bn in its Q4 2024 13F filing. The largest position was UTHR at 13.8% of the reported book, followed by ARGX and ASND. Against the Q3 2024 filing, it opened 7 new positions, added to 9 and reduced 7 among the top 39 holdings.
What did Avoro Capital Advisors LLC own in Q4 2024? Top 39 positions
| # | Stock | Sector | Weight | Value | Shares | Δ shares | vs Q3 2024 |
|---|---|---|---|---|---|---|---|
| 1 | UTHR UNITED THERAPEUTICS CORP | Healthcare | 13.8% | $973.9m | 2,760,300 | -3% | reduced |
| 2 | ARGX ARGENX SE | Healthcare | 10.8% | $761.7m | 1,238,467 | 0% | held |
| 3 | ASND ASCENDIS PHARMA | Healthcare | 9.9% | $702.5m | 5,103,055 | 2% | added |
| 4 | MDGL MADRIGAL PHARMACEUTICALS INC | Healthcare | 8.9% | $626.1m | 2,029,000 | 0% | held |
| 5 | KRYS KRYSTAL BIOTECH INC | Healthcare | 5.8% | $411.8m | 2,628,822 | 0% | held |
| 6 | APLSUSD APELLIS PHARMACEUTICALS INC. | 5.5% | $390.0m | 12,222,222 | 10% | added | |
| 7 | SRPT SAREPTA THERAPEUTICS INC | Healthcare | 4.4% | $310.7m | 2,555,555 | 0% | held |
| 8 | ITCIEUR INTRA-CELLULAR THERAPIES INC | 3.6% | $254.7m | 3,050,000 | 0% | held | |
| 9 | VERA VERA THERAPEUTICS INC | Healthcare | 3.4% | $237.2m | 5,610,000 | 30% | added |
| 10 | XENE XENON PHARMACEUTICALS INC | Healthcare | 3.1% | $222.1m | 5,666,666 | 0% | held |
| 11 | AM6 AMICUS THERAPEUTICS INC. | 3.1% | $218.3m | 23,175,000 | 0% | held | |
| 12 | RNAGBP AVIDITY BIOSCIENCES INC | 3.1% | $218.1m | 7,500,000 | 9% | added | |
| 13 | ARWR ARROWHEAD PHARMACEUTICALS INC. | Healthcare | 3.0% | $208.9m | 11,111,111 | 25% | added |
| 14 | KYMR KYMERA THERAPEUTICS INC | Healthcare | 2.9% | $207.2m | 5,150,000 | 14% | added |
| 15 | MLTX MOONLAKE IMMUNOTHERAPEUTICS | Healthcare | 2.1% | $150.0m | 2,770,100 | 0% | held |
| 16 | SLNOEUR SOLENO THERAPEUTICS INC | 1.6% | $113.5m | 2,525,000 | 16% | added | |
| 17 | 2655787D BLUEPRINT MEDICINES CORP | 1.5% | $103.4m | 1,185,000 | – | new | |
| 18 | PCVX VAXCYTE INC | Healthcare | 1.4% | $96.2m | 1,175,000 | 0% | held |
| 19 | BMRN BIOMARIN PHARMACEUTICAL INC | Healthcare | 1.4% | $96.1m | 1,462,500 | -28% | reduced |
| 20 | MERUS N V | 1.3% | $89.4m | 2,125,000 | 57% | added | |
| 21 | BCRX BIOCRYST PHARMACEUTICALS INC | Healthcare | 1.3% | $89.2m | 11,865,000 | 0% | held |
| 22 | ALKS ALKERMES PLC | Healthcare | 1.0% | $70.5m | 2,450,000 | – | new |
| 23 | OCUL OCULAR THERAPEUTIX INC | Healthcare | 1.0% | $68.8m | 8,060,000 | 0% | held |
| 24 | MNKD MANNKIND CORP | Healthcare | 0.8% | $56.3m | 8,750,000 | 0% | held |
| 25 | TRML TOURMALINE BIO INC | 0.6% | $45.1m | 2,222,222 | 0% | held | |
| 26 | QURE UNIQURE NV | 0.5% | $38.4m | 2,175,000 | – | new | |
| 27 | RARE ULTRAGENYX PHARMACEUTICAL INC | Healthcare | 0.5% | $34.9m | 830,000 | 0% | held |
| 28 | TSHA TAYSHA GENE THERAPIES INC | Healthcare | 0.5% | $34.6m | 19,999,999 | 7% | added |
| 29 | ETNBGBP 89BIO INC | 0.5% | $32.1m | 4,100,000 | – | new | |
| 30 | GLUE MONTE ROSA THERAPEUTICS INC | 0.4% | $30.2m | 4,345,000 | -25% | reduced | |
| 31 | SNDX SYNDAX PHARMACEUTICALS INC | Healthcare | 0.4% | $30.1m | 2,275,000 | -41% | reduced |
| 32 | IOVA IOVANCE BIOTHERAPEUTICS INC | Healthcare | 0.4% | $25.9m | 3,500,000 | -17% | reduced |
| 33 | SEPN SEPTERNA INC | 0.4% | $25.4m | 1,110,000 | – | new | |
| 34 | AUTL AUTOLUS THERAPEUTICS PLC | Healthcare | 0.3% | $23.3m | 9,910,642 | -20% | reduced |
| 35 | CGON CG ONCOLOGY INC | Healthcare | 0.3% | $20.1m | 700,000 | 0% | held |
| 36 | KURA KURA ONCOLOGY INC | Healthcare | 0.3% | $19.6m | 2,250,000 | -36% | reduced |
| 37 | RCKT ROCKET PHARMACEUTICALS INC | Healthcare | 0.2% | $15.1m | 1,200,000 | – | new |
| 38 | OLMA OLEMA PHARMACEUTICALS INC | Healthcare | 0.1% | $9.6m | 1,651,982 | – | new |
| 39 | WHWK AADI BIOSCIENCES INC | Healthcare | 0.1% | $9.0m | 2,849,402 | 0% | held |
Weights are shares of the reported long US equity book (options excluded). Values are as filed, normalised to whole dollars. Share changes compare against the immediately preceding filing only.